Creative Medical Technology Holdings, Inc. (CELZ)
(Real Time Quote from BATS)
$3.43 USD
+0.12 (3.63%)
Updated Sep 9, 2024 01:12 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Creative Medical Technology Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 6 | 10 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -6 | -10 | -3 | -1 | -1 |
Non-Operating Income | 0 | 0 | 27 | -34 | -5 |
Interest Expense | 0 | 0 | 4 | 1 | 2 |
Pretax Income | -5 | -10 | 19 | -36 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -5 | -10 | 19 | -36 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -5 | -10 | 19 | -36 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -10 | 1 | 0 | 1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 4 | 1 | 2 |
Income After Depreciation & Amortization | -6 | -10 | -3 | -1 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.41 | 1.09 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.76 | -9.30 | NA | NA | NA |
Diluted Net EPS (GAAP) | -3.76 | -9.30 | 56.10 | -1.30 | -8.20 |
Fiscal Year end for Creative Medical Technology Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 1.63 | 1.12 | 1.78 | 1.54 | 1.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.63 | -1.12 | -1.78 | -1.54 | -1.19 |
Non-Operating Income | 0.07 | 0.08 | 0.09 | 0.09 | 0.09 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.56 | -1.04 | -1.68 | -1.45 | -1.10 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.56 | -1.04 | -1.68 | -1.45 | -1.10 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.56 | -1.04 | -1.68 | -1.45 | -1.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.41 | 1.42 | 1.39 | 1.43 | 1.41 |
Diluted EPS Before Non-Recurring Items | -1.11 | -0.73 | -1.21 | -1.02 | -0.78 |
Diluted Net EPS (GAAP) | -1.11 | -0.73 | -1.26 | -1.02 | -0.78 |